Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 4(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04286503Phase 4Unknown

The Clinical Study of Carrimycin on Treatment Patients With COVID-19

Role: collaborator

NCT03633019Phase 4Unknown

High-dose Use of rhTPO in CIT Patients

Role: collaborator

NCT01611961Phase 1Unknown

Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients

Role: lead

All 3 trials loaded